These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26388771)

  • 1. What is synergy? The Saariselkä agreement revisited.
    Tang J; Wennerberg K; Aittokallio T
    Front Pharmacol; 2015; 6():181. PubMed ID: 26388771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.
    Kashif M; Andersson C; Mansoori S; Larsson R; Nygren P; Gustafsson MG
    Oncotarget; 2017 Nov; 8(61):103952-103967. PubMed ID: 29262612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive Dose Response Models: Defining Synergy.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2019; 10():1384. PubMed ID: 31849651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines.
    Roell KR; Reif DM; Motsinger-Reif AA
    Front Pharmacol; 2017; 8():158. PubMed ID: 28473769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Methods for Quantifying Drug Synergism.
    Ma J; Motsinger-Reif A
    Proteom Bioinform; 2019 Jul; 1(2):43-48. PubMed ID: 32043089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models.
    Baeder DY; Yu G; Hozé N; Rolff J; Regoes RR
    Philos Trans R Soc Lond B Biol Sci; 2016 May; 371(1695):. PubMed ID: 27160596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model.
    Goldoni M; Johansson C
    Toxicol In Vitro; 2007 Aug; 21(5):759-69. PubMed ID: 17420112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theory of synergistic effects: Hill-type response surfaces as 'null-interaction' models for mixtures.
    Schindler M
    Theor Biol Med Model; 2017 Aug; 14(1):15. PubMed ID: 28768512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interaction: focusing on response surface models.
    Lee SI
    Korean J Anesthesiol; 2010 May; 58(5):421-34. PubMed ID: 20532049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.
    Kashif M; Andersson C; Åberg M; Nygren P; Sjöblom T; Hammerling U; Larsson R; Gustafsson MG
    Mol Cancer Ther; 2014 Jul; 13(7):1964-76. PubMed ID: 24755197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel dose-response curves in combination experiments.
    Sühnel J
    Bull Math Biol; 1998 Mar; 60(2):197-213. PubMed ID: 9559575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2018; 9():31. PubMed ID: 29467650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.
    Meletiadis J; Verweij PE; TeDorsthorst DT; Meis JF; Mouton JW
    Med Mycol; 2005 Mar; 43(2):133-52. PubMed ID: 15832557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.
    Van der Borght K; Tourny A; Bagdziunas R; Thas O; Nazarov M; Turner H; Verbist B; Ceulemans H
    Sci Rep; 2017 Dec; 7(1):17935. PubMed ID: 29263342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mind the Curve: Dose-Response Fitting Biases the Synergy Scores across Software Used for Chemotherapy Combination Studies.
    Fuentealba-Manosalva O; Mansilla M; Buelvas N; Martin-Martin A; Torres CG; López-Muñoz RA
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical determination of synergy based on Bliss definition of drugs independence.
    Demidenko E; Miller TW
    PLoS One; 2019; 14(11):e0224137. PubMed ID: 31765385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charting the Fragmented Landscape of Drug Synergy.
    Meyer CT; Wooten DJ; Lopez CF; Quaranta V
    Trends Pharmacol Sci; 2020 Apr; 41(4):266-280. PubMed ID: 32113653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-parametric synergy modeling of chemical compounds with Gaussian processes.
    Shapovalova Y; Heskes T; Dijkstra T
    BMC Bioinformatics; 2022 Jan; 23(1):14. PubMed ID: 34991440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls.
    Vlot AHC; Aniceto N; Menden MP; Ulrich-Merzenich G; Bender A
    Drug Discov Today; 2019 Dec; 24(12):2286-2298. PubMed ID: 31518641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CombiTool--a new computer program for analyzing combination experiments with biologically active agents.
    Dressler V; Müller G; Sühnel J
    Comput Biomed Res; 1999 Apr; 32(2):145-60. PubMed ID: 10337496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.